ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Jane Wasman, President, International & General Counsel, is resigning from the company effective at the end of this year. Ms. Wasman plans to expand her role as a member of corporate boards, and to provide consulting services within the life sciences industry. She also will serve as a consultant to Acorda following her departure.
“Jane has contributed meaningfully to Acorda’s successes over the past 15 years. Her expertise and leadership have aided the company in its evolution throughout that time, as she headed functions ranging from legal to QA, international and strategic development,” said Ron Cohen, Acorda’s President and CEO. “While we will miss her, we support her entering a new phase of her career, and are delighted that she will continue an association with the company.”
“I am proud to have been part of the team that grew Acorda from a private, clinical-stage company to a public, commercial company that has brought important new medicines to people suffering with Parkinson’s disease and multiple sclerosis,” Ms. Wasman said. “I am looking forward to the next chapter of my career focusing on boards and consulting, including with Acorda.”
Andrew Mayer, Acorda’s Deputy General Counsel, will assume responsibility for legal operations following Ms. Wasman’s departure.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
